Download Free Medical Understanding Genetics of Schizophrenia PowerPoint Presentation

Understanding Genetics of Schizophrenia PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Understanding Genetics of Schizophrenia" by Carlos N. Pato, M.D. , PhD.
This medical PowerPoint presentation talks about Schizophrenia, a complex and multifactorial mental disorder that has a significant genetic component.

Tags : Genetics of Schizophrenia, Schizophrenia, Genetics, Genetics PowerPoint presentation

Published on : Mar 27, 2023 | Views : 568 | Downloads : 0

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Understanding Genetics of Schizophrenia Carlos N. Pato, M.D. , Ph.D. Professor and Chair of Psychiatry Center for Genomic Psychiatry Keck School of Medicine University of Southern California
Slide 2-

Lifetime Risk for Schizophrenia Schizophrenia 0.5-1.0% General Population 10-15% If a parent or sibling (including dizygotic twin) is schizophrenic 40% If both parents are schizophrenic 45-75% If monozygotic twin is schizophrenic (Same risk to children- Fisher)
Slide 3-

Genes (DNA) do not read the DSM-IV.
Slide 4-

Phenotype Definition A C H D Schizophrenia Bipolar Disorder Psychosis G F E J B
Slide 5-

Genetic Strategies What is linkage ? What is a LOD score or a NPL ? What is an association ? How to understand statistical significance. Candidate genes Genome wide scans (genomic mapping) Gene expression arrays
Slide 6-

Schizophrenia on Chromosome 5q
Slide 7-

Region rich in candidate genes Glutamate receptor-GRIA1 GABA cluster-GABRA1, GABRA2 Serotonin Receptor-HTR4 Glycine Receptor-GLRA1 Glucocorticoid receptor-NR3C1 Adrenergic receptor-ADRB2 Neuregulin-NRG2 Kinase-CAMK2A
Slide 8-

Human Mapping Assay A rapid, reliable and cost-effective assay for simultaneously genotyping many thousands of SNPs distributed across the genome Accuracy >99%
Slide 9-

Transcript probes with the highest diagnostic utility for distinguising BP, SCZ, and control subjects The expression patterns of the 35 most predictive genes correctly classified all BP and control subjects and 27 of 33 SCZ subjects.
Slide 10-

Genome-wide Survey of CNVsNature (2008) 3380 patients with schizophrenia and 3139 ancestrally-matched controls identified three regions large (>500kb) deletions increase disease risk Deletions easier to detect because of their size and replicability compared to single point mutations (single SNP)
Slide 11-

Genome-wide Survey of CNVsNature (2008) On chromosome 22q11.2 - identified deletions in ~0.3% of schizophrenia patients (P =0.00056 versus controls) Odds ratio = 21.6
Slide 12-

Genome-wide Survey of CNVsChromosome 22 deletion
Slide 13-

Genome-wide Survey of CNVsNature (2008) On chromosome 15q13.2- identified deletions in ~0.3% of schizophrenia patients (P =0.00056 versus controls) Odds ratio= 17.9
Slide 14-

Genome-wide Survey of CNVsChromosome 15
Slide 15-

Genome-wide Survey of CNVsNature (2008) On chromosome 1q21.1 - identified deletions in ~0.3% of schizophrenia patients (P =0. 0.024 versus controls) Odds ratio= 6.6
Slide 16-

Genome-wide Survey of CNVsChromosome 1
Slide 17-

Genome-wide Survey of CNVsNature (2008) In the same issue of Nature, a parallel paper by DeCode showed the same results Extremely strong evidence for these relatively rare mutations Proves the necessity for extremely large studies
Slide 18-

Common polygenic variation contributes to risk Rare variants likely to contribute to risk major histocompatibility complex strongly replicated association with schizophrenia MHC and Common VariantsNature, 2009
Slide 19-

Genomic Psychiatry Cohort We have established the goal of studying 30,000 patients and 30,000 controls Schizophrenia and Bipolar disorder We have begun to bring together the funding for this large-scale program The NIMH launched this program with an initial $25 million dollars in grants to USC and MGH/Broad
Slide 20-

Future Directions Gene identification Gene expression Proteomics Treatment development At risk studies- with a focus on development of pre-clinical diagnosis + treatment